CHICAGO – With the publication of a paper validating two artificial intelligence-based algorithms for assisting pathologists in molecular profiling of patients, the Genomic Testing Cooperative
Background VEXAS syndrome is a disease with inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene affecting the Met41 residue of
Irvine, California– June 1, 2022 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the American Society of Clinical Oncology (ASCO)
IRVINE, California, May 25, 2022 – Genomic Testing Cooperative (GTC) today announced it received CE-IVD marks for its Hematology Profile Plus, Solid Tumor Plus as
Abstract Multiple studies have demonstrated that diffuse large B-cell lymphoma (DLBCL) can be divided into subgroups based on their biology; however, these biological subgroups overlap
GTC is excited to be exhibiting at ASH for the first time and look forward to meeting people in person. Our booth # 3440 and would
Distinguishing PH-like acute lymphoblastic leukemia (ALL) from other types of ALL relies on full evaluation of the molecular abnormalities in the leukemic cells. Order GTC
We’re always competing with ourselves on improving turn around time (TAT) because we know patients depend on the results Most studies suggest that treatment delay
Time Matters on Health Tests When dealing with cancer, clinicians and patients need to know the results of molecular testing as soon as possible. Are
-a step forward to precision in cancer diagnostics- CSI LABORATORIES ADVANCES BY PARTNERING WITH DR. MAHER ALBITAR OF GENOMICS TESTING COOPERATIVE (GTC) Membership in the Co-Op also
